The program will bring together experts from across the FDA for a team-based review, rather than having an application move ...

Nearly $30 million in tax incentive awards are expected to add 1,519 new life sciences jobs in Massachusetts, with about 52% ...

The pending deal was rumored overnight after a report from the Financial Times, spurring analysts to speculate that if true, ...

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

HHS Secretary Robert F. Kennedy Jr.’s actions in recent months have raised concerns that he is taking a heavy-handed and ...

At a satellite kickoff event to the annual BIO meeting, investment bankers and VCs gave reasons for optimism amid a ‘volatile ...

Big Pharma executives have not been shy about their desire for deals, but companies have been battling macro headwinds ...

Jefferies analysts said on Tuesday that Ventyx could leverage its mid-stage data for VTX3232 to position the oral drug candidate as a treatment for other neurodegenerative diseases, including ...

NextCure is joining the China biopharma gold rush, partnering with Simcere Pharmaceutical Group on development of a novel ...

AstraZeneca, Pfizer and more are leveraging the computational power of AI to better design trials, predict the potential ...

While cancelled NIH grants and regulatory uncertainty are less hospitable to clinical research in the U.S., Europe must play ...

Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in ...